Aclaris in alopecia patent license pact with Sun Pharma includes $15M upfront

Aclaris Therapeutics announced an exclusive patent license agreement with Sun Pharmaceutical Industries or Sun Pharma. Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata or AA or androgenetic alopecia AGA . The agreement includes an upfront payment of $15M, regulatory and commercial milestones, and royalties. Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma. “We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated James Loerop, Chief Business Officer of Aclaris.